MA40065B1 - N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson - Google Patents

N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson

Info

Publication number
MA40065B1
MA40065B1 MA40065A MA40065A MA40065B1 MA 40065 B1 MA40065 B1 MA 40065B1 MA 40065 A MA40065 A MA 40065A MA 40065 A MA40065 A MA 40065A MA 40065 B1 MA40065 B1 MA 40065B1
Authority
MA
Morocco
Prior art keywords
disease
parkinson
bis
treatment
mercaptoethyl isophthalamide
Prior art date
Application number
MA40065A
Other languages
English (en)
Other versions
MA40065A (fr
Inventor
Boyd Eugene Haley
Ragnar Axel Theodor Klingberg
Original Assignee
Emeramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emeramed Ltd filed Critical Emeramed Ltd
Publication of MA40065A publication Critical patent/MA40065A/fr
Publication of MA40065B1 publication Critical patent/MA40065B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne du n,n-bis-2-mercaptoéthyle isophthalamide, ou un sel pharmaceutiquement acceptable ou un dérivé de celui-ci, à utiliser dans le traitement thérapeutique d'un trouble neurodégénératif de type maladie d'alzheimer, maladie de parkinson, maladie de huntington et/ou sclérose latérale amyotrophique.
MA40065A 2014-05-30 2015-05-29 N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson MA40065B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1409662.2A GB2526623A (en) 2014-05-30 2014-05-30 New pharmaceutical use
PCT/GB2015/051572 WO2015181567A1 (fr) 2014-05-30 2015-05-29 N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de maladies neurodégénératives

Publications (2)

Publication Number Publication Date
MA40065A MA40065A (fr) 2021-05-19
MA40065B1 true MA40065B1 (fr) 2021-09-30

Family

ID=51214502

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40065A MA40065B1 (fr) 2014-05-30 2015-05-29 N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson
MA54630A MA54630B1 (fr) 2014-05-30 2020-02-06 N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA54630A MA54630B1 (fr) 2014-05-30 2020-02-06 N,n-bis-2-mercaptoéthyle isophtalamide pour le traitement des maladies neurodégénératives

Country Status (16)

Country Link
US (4) US20170202791A1 (fr)
EP (2) EP3148588B1 (fr)
CY (1) CY1124509T1 (fr)
DK (2) DK3148588T3 (fr)
ES (2) ES2938080T3 (fr)
FI (1) FI3903774T3 (fr)
GB (1) GB2526623A (fr)
HR (2) HRP20230105T1 (fr)
HU (2) HUE055575T2 (fr)
LT (2) LT3903774T (fr)
MA (2) MA40065B1 (fr)
PL (2) PL3148588T3 (fr)
PT (2) PT3903774T (fr)
RS (2) RS63859B1 (fr)
SI (2) SI3148588T1 (fr)
WO (1) WO2015181567A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005057D0 (en) 2020-04-06 2020-05-20 Emeramed Ltd New Use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586600B2 (en) 2000-12-06 2003-07-01 University Of Kentucky Research Foundation Multidentate sulfur-containing ligands
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
US8950583B2 (en) * 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
US8575218B2 (en) 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
IN2012DN02586A (fr) 2009-09-28 2015-08-28 Univ Kentucky Res Found
US20110237776A1 (en) 2010-03-25 2011-09-29 Haley Boyd E Aromatic compounds with sulfur containing ligands
US8426368B2 (en) 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet

Also Published As

Publication number Publication date
US11628151B2 (en) 2023-04-18
MA54630A (fr) 2021-11-03
ES2938080T3 (es) 2023-04-04
RS62095B1 (sr) 2021-08-31
PL3903774T3 (pl) 2023-03-13
US20220287994A1 (en) 2022-09-15
LT3148588T (lt) 2021-08-10
SI3903774T1 (sl) 2023-03-31
GB201409662D0 (en) 2014-07-16
US20230013704A1 (en) 2023-01-19
HRP20230105T1 (hr) 2023-03-17
HUE055575T2 (hu) 2021-12-28
ES2882977T3 (es) 2021-12-03
DK3903774T3 (da) 2023-01-16
HRP20211309T1 (hr) 2021-11-26
EP3903774B1 (fr) 2022-11-09
PL3148588T3 (pl) 2021-12-13
PT3148588T (pt) 2021-07-15
US20180250247A1 (en) 2018-09-06
EP3148588A1 (fr) 2017-04-05
WO2015181567A1 (fr) 2015-12-03
HUE060927T2 (hu) 2023-04-28
SI3148588T1 (sl) 2022-01-31
EP3903774A1 (fr) 2021-11-03
RS63859B1 (sr) 2023-01-31
MA54630B1 (fr) 2023-01-31
MA40065A (fr) 2021-05-19
US20170202791A1 (en) 2017-07-20
LT3903774T (lt) 2023-01-10
DK3148588T3 (en) 2021-07-26
FI3903774T3 (fi) 2023-04-12
CY1124509T1 (el) 2022-07-22
GB2526623A (en) 2015-12-02
PT3903774T (pt) 2022-12-23
EP3148588B1 (fr) 2021-06-23

Similar Documents

Publication Publication Date Title
MA49402A (fr) Polynucléotides aadc pour le traitement de la maladie de parkinson
EP3268086A4 (fr) Lsd pour le traitement de la maladie d'alzheimer
IL263433A (en) Methods for treating Alzheimer's disease
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
EP3377118A4 (fr) Méthodes pour traiter la maladie d'alzheimer et des troubles associés
EP3419622A4 (fr) Traitement d'une maladie neurodégénérative de l'oeil à l'aide de pridopidine
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
SI3463351T1 (sl) Zdravljenje parkinsove bolezni
MA47395A (fr) Méthode pour le traitement d'une maladie neurologique
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
EP3702470A3 (fr) Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer
MA47595A (fr) Méthodes de traitement d'affections neurodégénératives
IL264040A (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
FR3044227B1 (fr) Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
EP3490546A4 (fr) Méthodes de traitement ou de prévention des anomalies, observées en imagerie, qui sont liées à l'immunisation contre l'amyloïde, associées au traitement de la maladie d'alzheimer
MA40065B1 (fr) N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson
MA39833B1 (fr) Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide
FR3057455B1 (fr) Equipement pour le traitement d'une fracture par haubanage, par exemple d'une fracture de l'olecrane ou de la rotule
EP3601570A4 (fr) Méthodes de traitement de la maladie d'alzheimer
AU2017902307A0 (en) Treatment of alzheimer's disease
AU2017902309A0 (en) Treatment of alzheimer's disease
AU2018903530A0 (en) Treatment for Alzheimer's Disease
GB201819758D0 (en) Medicine for the treatment of Alzheimer's disease
EP3804766A4 (fr) Agent thérapeutique contre la maladie d'alzheimer